<?xml version='1.0' encoding='utf-8'?>
<document id="11098718"><sentence text="More than cholesterol: the complexity of coronary artery disease."><entity charOffset="10-21" id="DDI-PubMed.11098718.s1.e0" text="cholesterol" /></sentence><sentence text="There have been many recent articles published that emphasize the fact that cholesterol deposits are only one of many mechanisms through which acute coronary artery disease develops"><entity charOffset="76-87" id="DDI-PubMed.11098718.s2.e0" text="cholesterol" /></sentence><sentence text=" Recently, a meta-analysis shows that only 14% of acute coronary events occur in stenotic lesions in coronary arteries that are greater than 70% occluded" /><sentence text=" The majority of acute coronary events (68%) occur in coronary arteries that have less than 50% stenotic lesions" /><sentence text=" The acute coronary syndrome is a very complex and unpredictable disease" /><sentence text=" Recent information now points to the endothelium as a modulating factor in the pathogenesis of coronary artery disease through the production of nitric oxide and angiotensin-II which maintain the homeostatic environment influencing the progression of coronary artery disease"><entity charOffset="146-158" id="DDI-PubMed.11098718.s6.e0" text="nitric oxide" /></sentence><sentence text=" With dysfunctional endothelium there seems to be an imbalance in terms of angiotensin production with regards to the nitric oxide production"><entity charOffset="75-86" id="DDI-PubMed.11098718.s7.e0" text="angiotensin" /><entity charOffset="118-130" id="DDI-PubMed.11098718.s7.e1" text="nitric oxide" /><pair ddi="false" e1="DDI-PubMed.11098718.s7.e0" e2="DDI-PubMed.11098718.s7.e0" /><pair ddi="false" e1="DDI-PubMed.11098718.s7.e0" e2="DDI-PubMed.11098718.s7.e1" /></sentence><sentence text=" This imbalance tends to promote coronary artery disease in individuals who have multiple risk factors" /><sentence text=" Furthermore, it has been suggested that certain inflammatory compounds are produced in a very dysfunctional endothelium, thereby propagating or leading to acute coronary syndromes" /><sentence text=" Specifically, this includes C-reactive protein which promotes chronic inflammation at various sites" /><sentence text=" There are also other acute phase reactants, such as fibrinogen, which may play a role in atherogenesis" /><sentence text=" Certain statin drugs, as they are called, tend to ameliorate the levels of the above acute phase reactants, while other statins do not" /><sentence text=" This reduction of coronary events by statins is independent of the LDL lowering benefits from statin drugs" /><sentence text=" This article delineates some of the beneficial effects of the different statin agents and points out that all statins are not equal in terms of their known lipid beneficial effects" /><sentence text=" For the practicing physician, choosing a particular statin agent is important" /><sentence text=" Some have more drug/drug interaction potential as compared with the others because of their inability to be metabolized through the cytochrome P450 system" /><sentence text=" There are also some, because of their lipophilic and hydrophilic nature, that tend to enter cells more readily than other statin agents" /><sentence text=" The effects conferred by these subtle differences among the currently available statins tend to be beneficial in patients with low to moderate levels of LDL cholesterol"><entity charOffset="158-169" id="DDI-PubMed.11098718.s18.e0" text="cholesterol" /></sentence><sentence text="" /></document>